一、董事会会议召开情况 证券代码：003006 证券简称：百亚股份 公告编号：2025-003 重庆百亚卫生用品股份有限公司 第四届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 《2024 年度董事会工作报告》具体内容详见公司同日在巨潮资讯网 （www.cninfo.com.cn）披露的《2024 年年度报告》相关章节内容。 公司现任独立董事江积海先生、郝颖先生、马赟先生，离任独立董事侯茜女 士、晏国菀女士提交了《2024 年度独立董事述职报告》，并将在公司 2024 年年度 股东大会上述职。此外，公司现任独立董事向公司董事会提交了《独立董事关于 独立性自查情况的报告》，公司董事会对现任独立董事独立性情况进行评估并出 具了《董事会关于独立董事独立性自查情况的专项报告》。具体内容详见公司同 日在巨潮资讯网披露的《2024 年度独立董事述职报告》《董事会关于独立董事独 立性自查情况的专项报告》。 本议案尚需提交公司股东大会审议。 重庆百亚卫生用品股份有限公司（以下简称"公司"）第四届董事会第四次 会议于 2025 年 3 月 21 日在 ...

重庆百亚卫生用品股份有限公司 2024 年年度报告全文 重庆百亚卫生用品股份有限公司 2024 年年度报告 2025 年 3 月 1 重庆百亚卫生用品股份有限公司 2024 年年度报告全文 2024 年年度报告 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人冯永林、主管会计工作负责人张黎及会计机构负责人（会计主 管人员）张黎声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的公司发展战略和规划等前瞻性陈述，不构成公司对投资者 的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理 解计划、预测与承诺之间的差异。 公司面临市场竞争日益加剧、原材料价格波动和营销网络拓展的风险，具 体详细内容见本报告"第三节管理层讨论与分析"之"十一、公司未来发展的展 望"之"(三)可能面临的风险"，敬请广大投资者注意。 公司经本次董事会审议通过的利润分配预案为：以 429,323,390股为基数， 向全体股东每 1 ...

证券代码：003006 证券简称：百亚股份 公告编号：2025-016 重庆百亚卫生用品股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重庆百亚卫生用品股份有限公司（以下简称"公司"）于 2025 年 3 月 21 日 召开的第四届董事会第四次会议和第四届监事会第四次会议分别审议通过了《关 于 2024 年度利润分配预案的议案》，该议案尚需提交公司股东大会审议，现将相 关情况公告如下： 一、审议程序 1、董事会审议情况 2025 年 3 月 21 日，公司第四届董事会第四次会议审议通过了《关于 2024 年度利润分配预案的议案》，同意将本次利润分配预案提交公司股东大会审议。 2、监事会审议情况及意见 2025 年 3 月 21 日，公司第四届监事会第四次会议审议通过了《关于 2024 年度利润分配预案的议案》。经审核，监事会认为：公司 2024 年度利润分配预案 充分考虑了公司经营状况及未来发展的资金需求等综合因素，与公司实际经营业 绩匹配，有利于维护公司全体股东的长期利益，保证公司的稳定经营和健康发展； ...

证券代码：003006 证券简称：百亚股份 公告编号：2025-002 回复说明： 经核查，公司对报道中所述违规业务并不知悉，且公司未曾参与此类违规业 务。公司与涉事违规公司不存在交易往来，亦不存在关联关系、合作关系。 问题二：你公司有关原材料采购、生产残次品处置的制度和实际执行情况， 内部控制机制是否有效运转，是否存在采购不合格原材料、残次品违规流通或者 处置的漏洞，如是，你公司拟采取的整改完善、消除影响措施。 回复说明： 关于对深圳证券交易所关注函回复的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重庆百亚卫生用品股份有限公司（以下简称"公司"）于 2025 年 3 月 16 日 收到深圳证券交易所（以下简称"深交所"）上市公司管理一部下发的《关于对 重庆百亚卫生用品股份有限公司的关注函》（公司部关注函（2025）第 2 号，以 下简称"关注函"），要求公司就所提问题进行核实并做出书面说明并对外披露， 同时抄送重庆证监局上市公司监管处。 公司收到关注函后高度重视，立即组织相关部门对涉及的相关问题逐项进行 认真核查与落实，现将有关情况回复如下： 问题 ...

人民财讯3月17日电，3月17日，百亚股份跌停开盘、稳健医疗低开超8%。 2025年"3·15"晚会曝光违规翻新卫生巾事件后，"自由点"卫生巾母公司百亚股份在3月16日早间收到深 交所下发的关注函。 同日，全棉时代母公司稳健医疗也收到了深交所下发的关注函，对上述问题同样进行了追问。 ...

请公司自查并说明：一、你公司是否知悉、参与报道所述违规业务，和涉事违规公司是否存在交易往来 或者应予说明的关联、合作关系。 二、你公司有关原材料采购、生产残次品处置的制度和实际执行情况，内部控制机制是否有效运转，是 否存在采购不合格原材料、残次品违规流通或者处置的漏洞，如是，你公司拟采取的整改完善、消除影 响措施。 人民财讯3月16日电，3月16日，百亚股份收到深交所关注函。 有媒体报道某纸制品有限公司（简称"涉事违规公司"）收购品牌纸尿裤和卫生巾残次品，违规翻新后销 售，或者处理形成回收料回售，其中提及公司品牌产品。 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][6][18] Core Views - The company has achieved top rankings on multiple e-commerce platforms, including Tmall and Pinduoduo, which sets a strong foundation for the upcoming March 8th sales campaign [1][2] - The management team and distributors are actively engaged in promoting the brand and utilizing innovative marketing strategies to enhance store performance during the March 8th festival [2][3] - The company is focusing on brand strength and customer acquisition through various marketing initiatives, including collaborations with brand ambassadors and unique promotional events [3][4] Financial Projections - The company expects to achieve a net profit of 290 million, 370 million, and 480 million yuan for the years 2024, 2025, and 2026 respectively, with corresponding P/E ratios of 35, 27, and 21 [4][5] - Revenue is projected to grow significantly from 1.61 billion yuan in 2022 to 5.30 billion yuan by 2026, reflecting a compound annual growth rate (CAGR) of approximately 24.61% [5][12] - The EBITDA is expected to increase from 318.54 million yuan in 2022 to 647.84 million yuan in 2026, indicating strong operational performance [5][12] Key Financial Metrics - The company's earnings per share (EPS) is projected to rise from 0.44 yuan in 2022 to 1.12 yuan in 2026 [5][12] - The gross margin is expected to improve from 45.11% in 2022 to 54.19% in 2026, showcasing enhanced profitability [13] - The asset-liability ratio is forecasted to increase from 26.05% in 2022 to 35.48% in 2026, indicating a stable financial structure [13]

Investment Rating - The report maintains a "Buy" rating for the company [4][6][17] Core Views - The company has achieved top rankings on multiple e-commerce platforms, including Tmall and Pinduoduo, which sets a strong foundation for the upcoming marketing campaign [1][2] - The management team is actively engaging with distributors to ensure effective execution of the marketing strategies for the upcoming Women's Day campaign [2] - The company is enhancing brand strength through online and offline collaboration, including hosting live sessions and artistic events to connect with target demographics [3] Financial Projections - The company forecasts a net profit attributable to the parent company of 290 million, 370 million, and 480 million for the years 2024, 2025, and 2026 respectively, with corresponding P/E ratios of 35, 27, and 21 [4][5] - Revenue is projected to grow from 1.61 billion in 2022 to 5.30 billion in 2026, reflecting a compound annual growth rate (CAGR) of approximately 24.61% [5][12] - The EBITDA is expected to increase from 318.54 million in 2022 to 647.84 million in 2026, indicating a strong operational performance [5][12]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [5][16]. Core Insights - The company has proposed six new strategies to tackle increasing competition in the sanitary napkin industry, including new product structures, promotional scenarios, and user expansion [1]. - The company is focusing on expanding its market presence in peripheral provinces, with significant growth in sales expected outside its core five provinces [3]. - The financial forecast for the company shows a steady increase in revenue and net profit, with projected EPS of 0.66 yuan, 0.87 yuan, and 1.12 yuan for 2024, 2025, and 2026 respectively [4]. Financial Data and Valuation - The company's revenue is projected to grow from 1,612.14 million yuan in 2022 to 5,298.46 million yuan in 2026, reflecting a compound annual growth rate (CAGR) of approximately 24.61% [4][11]. - The EBITDA is expected to increase from 318.54 million yuan in 2022 to 647.84 million yuan in 2026, indicating improved operational efficiency [4]. - The projected PE ratios for 2024, 2025, and 2026 are 34x, 26x, and 20x respectively, suggesting a favorable valuation trend as earnings grow [4]. Market Strategy - The company is implementing a "Spring Thunder Action" across various regions to enhance market penetration and resource allocation, aiming for a competitive edge in the market [2]. - The focus on health-oriented products, particularly those featuring probiotics, is expected to drive revenue growth and market share expansion in key provinces like Guangdong, Hunan, and Jiangsu [3].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company reported impressive revenue performance with a total revenue of 3.255 billion yuan in 2024, representing a year-on-year growth of 51.8%. The net profit attributable to the parent company was 285 million yuan, up 19.7% year-on-year [6] - Multiple growth drivers are accelerating, including the continued success of probiotic products, high growth in e-commerce revenue, steady offline national expansion, and a proactive management team [6] - The company focuses on health products, particularly probiotics, with revenue from the "Free Point" brand reaching 3.037 billion yuan in 2024, a 60.7% increase year-on-year [6] - E-commerce revenue grew significantly, achieving 1.525 billion yuan in 2024, a 103.8% increase year-on-year, driven by strong brand presence on platforms like Douyin and Tmall [6] - Offline expansion is also progressing, with revenue from offline channels reaching 1.616 billion yuan, a 26.8% increase year-on-year, particularly in peripheral markets [6] Financial Data and Profit Forecast - Total revenue is projected to grow from 2.144 billion yuan in 2023 to 5.646 billion yuan by 2026, with a compound annual growth rate (CAGR) of approximately 29.4% [4] - The gross profit margin is expected to improve from 53.1% in 2024 to 56.6% in 2026, reflecting a positive trend in product positioning and sales [4] - The return on equity (ROE) is forecasted to increase from 19.7% in 2024 to 26.8% in 2026, indicating enhanced profitability [4]